Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Mirabegron is a prescription beta-3 adrenergic receptor agonist also marketed as Myrbetriq. Extended-release tablets are indicated for overactive bladder in adults and neurogenic detrusor overactivity in children age 3 and older weighing at least 35 kg. Current tablet strengths include 25 mg and 50 mg. Oral granules have separate pediatric dosing instructions.
read more about mirabegron ...Mirabegron activates beta-3 adrenergic receptors in the bladder's detrusor muscle during the storage phase. This relaxes the muscle and increases bladder storage capacity. Its action helps reduce urinary urgency, frequent urination, and episodes of urge urinary incontinence.
Mirabegron extended-release tablets treat adults with overactive bladder symptoms, including urgency, urinary frequency, and urge urinary incontinence. They also treat neurogenic detrusor overactivity in pediatric patients age 3 and older weighing at least 35 kg. Children below that weight require evaluation for an appropriate oral granule formulation. Patients with severe uncontrolled hypertension generally should not receive mirabegron.
Adults with overactive bladder usually start at 25 mg once daily, increasing to 50 mg daily after four to eight weeks when needed. Pediatric patients weighing at least 35 kg follow the same tablet starting dose and potential increase for neurogenic detrusor overactivity. Adults take the extended-release tablets with or without food, while children take them with food. Tablets are swallowed whole. Kidney or liver impairment can require lower doses.
Mirabegron can increase blood pressure and cause urinary retention, particularly in patients with bladder outlet obstruction or those taking certain other bladder medicines. Severe swelling of the face, tongue, or throat from angioedema can be life-threatening. Mirabegron also inhibits CYP2D6, which can increase exposure to medicines such as metoprolol. Blood pressure and urinary symptoms are monitored during treatment.
Mirabegron treats overactive bladder in adults and neurogenic detrusor overactivity in eligible pediatric patients.
The recommended starting dose of extended-release tablets is 25 mg once daily.
Yes. Extended-release tablets are indicated for neurogenic detrusor overactivity from age 3 in children weighing at least 35 kg.
Yes. Mirabegron can increase blood pressure and is not recommended for patients with severe uncontrolled hypertension.
DailyMed - MIRABEGRON tablet, extended release. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b71b939e-8cb1-492c-8311-28f75dc4c682. Date Accessed October 14, 2026.
Mirabegron. LiverTox. https://www.ncbi.nlm.nih.gov/books/NBK547887/. Date Accessed October 14, 2026.
Mirabegron. MedlinePlus. https://medlineplus.gov/druginfo/meds/a612038.html. Date Accessed October 14, 2026.
Mirabegron. PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/Mirabegron. Date Accessed October 14, 2026.
Mirabegron. StatPearls. https://www.ncbi.nlm.nih.gov/books/NBK538513/. Date Accessed October 14, 2026.